Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CRHBP | P24387 | 3/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DBH | P09172 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22640056 | 1.00 | TDP1 (0.57) | TDP1KMT2ACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL19617763 | 0.82 | SIGMAR1 (0.57) | KMT2AALDH1A1L3MBTL1MAPTLMNA | |
| SCHEMBL22640117 | 0.80 | ALDH1A1 (0.52) | KMT2AALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL22640155 | 0.80 | ALDH1A1 (0.52) | KMT2AALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL5190544 | 0.75 | ALDH1A1 (0.56) | KMT2AALDH1A1L3MBTL1LMNAMAPK1 | |
| SCHEMBL23496876 | 0.75 | SIGMAR1 (0.54) | KMT2AALDH1A1LMNAGAA | |
| SCHEMBL6008090 | 0.75 | SIGMAR1 (0.54) | KMT2AALDH1A1LMNAGAA | |
| SCHEMBL3948948 | 0.75 | SIGMAR1 (0.54) | KMT2AALDH1A1LMNAGAA | |
| SCHEMBL9842333 | 0.74 | ALDH1A1 (0.50) | KMT2AALDH1A1L3MBTL1LMNAMAPK1 | |
| SCHEMBL5190692 | 0.72 | ALDH1A1 (0.48) | KMT2AALDH1A1L3MBTL1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | TDP1 2894/4885KMT2A 4613/4885CRHBP 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.